Mr. Lewis did say in the last Conference that they would put out a PR when they finally reach the 100 patient enrollment for the NTM trial. Doesn't seem like it is THAT big of a deal but it's pretty clear that it has taken much longer than originally anticipated. On the plus side, though, sounding like they will not need a PH III before applying for an NDA which is terrific for patients and shareholders.
first qtr 2014 - company has stated at the last 3 or 4 conferences....which is actually better because of the time frame ( January effect/bio seasonality )..say 4 mos is plenty of time to trade INSM...just look at how the shorts have pumped it up in only 4 weeks! Have a fun weekend.....................Good Luck
"just look at how the shorts have pumped it up in only 4 weeks! "
Shorts scrambling to cover from, like 11-16 made the price go up? Now that IS funny.
I don't know who you think is dumb enough to think you mean that. Except maybe you.
And you don't need to tell any of us longs to have a Fun weekend. That is already well assured.
Where the schedule of milestones has changed is over in the "History" section and then in the clinical trial protocol itself. What it suggests is that the endpoint has slid by about 5 months. If you remember, there was a very protracted period where the NIH collaborative study sites were slow coning online. This was probably because of IRB scheduling and questions. Remember each of the trial sites had to get approval for the clinical trial on an institution-by-institution basis. There cannot be a clinical trial at any health sciences institution without IRB approval by that institutional committee. Usually IRBs have at least two "lay persons" representing the general public. These unaffiliated members are responsible for ensuring that the clinical trial is in "public interest." It evolved from the need to ensure "informed consent" which evolved from the Neuremburg Trials of WWII. But anyway, the protocols were slow to come online and then there were probably lots of waiting events associated with the 6 month prior Rx by the approve inhouse regimen to treat NTM. That is why it was very encouraging to hear Will Lewis say INSM was going for (and I think they got approval for) and EAP for NTM.
Sentiment: Strong Buy